NCT00039104View on ClinicalTrials.gov

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

January 31, 2005

Conditions
Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate Cancer
Interventions
DRUG

rebimastat

Given PO

DRUG

zoledronic acid

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00039104 - Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter